Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.69 USD
-0.06 (-3.43%)
Updated May 14, 2024 10:10 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 161 - 180 ( 393 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
We are placing shares of NKTR Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Q3 Inline, Guidance Raised; Most Impressive- NKTR-181 NDA Filing in April
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
PAINWeek Conference Abstracts Reveal New Withdrawal Data on NKTR-181
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M